Das intestinale Mikrobiom bei gastroenterologischen Krankheitsbildern

Zwischen dem intestinalen Mikrobiom und dem Individuum besteht eine intensive, lebenslange Wechselwirkung. Das Mikrobiom reguliert physiologische Prozesse und ist gleichzeitig Zielstruktur für regulatorische Eingriffe des Wirts. In den letzten Jahren konnte gezeigt werden, dass das intestinale Mikrobiom aufgrund dieser Stellung eine wichtige Rolle bei einer Vielzahl von gastroenterologischen Krankheitsbildern spielt, aber auch eine wichtige therapeutische Option darstellen kann.

Schlüsselwörter

intestinales Mikrobiom - PSC - Reizdarm - Clostridioides difficile - fäkaler Mikrobiomtransfer - Kolonkarzinom

Keywords

intestinal microbiome - irritable bowel syndrome - Clostridioides difficile - faecal microbiome transfer - colon cancer

• Literatur

• 1 Faith JJ, Guruge JL, Charbonneau M. et al. The long-term stability of the human gut microbiota. Science 2013; 341: 1237439
• 2 Krishnan S, Eslick GD. Streptococcus bovis infection and colorectal neoplasia: a meta-analysis. Colorectal Dis 2014; 16: 672-680
• 3 Wirbel J, Pyl PT, Kartal E. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med 2019; 25: 679-689
• 4 Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol 2023; 20: 429-452
• 5 Dejea CM, Fathi P, Craig JM. et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 2018; 359: 592-597
• 6 Rubinstein MR, Wang X, Liu W. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating e-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013; 14: 195-206
• 7 Patra S, Sahu N, Saxena S. et al. Effects of probiotics at the interface of metabolism and immunity to prevent colorectal cancer-associated gut inflammation: a systematic network and meta-analysis with molecular docking studies. Front Microbiol 2022; 13: 878297
• 8 Marshall JK, Thabane M, Garg AX. et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010; 59: 605-611
• 9 Villani A, Lemire M, Thabane M. et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-1513
• 10 Pittayanon R, Lau JT, Yuan Y. et al. Gut microbiota in patients with irritable bowel syndrome–a systematic review. Gastroenterology 2019; 157: 97-108
• 11 So D, Loughman A, Staudacher HM. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. Am J Clin Nutrition 2022; 116: 943-952
• 12 Vervier K, Moss S, Kumar N. et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut 2022; 71: 1821-1830
• 13 Bai T, Xu Z, Xia P. et al. The short-term efficacy of bifidobacterium quadruple viable tablet in patients with diarrhea-predominant irritable bowel syndrome: potentially mediated by metabolism rather than diversity regulation. Am J Gastroenterol 2023; 118: 1256-1267
• 14 Holvoet T, Joossens M, Vázquez-Castellanos JF. et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology 2021; 160: 145-157.e8
• 15 Liao JX, Appaneal HJ, Vicent ML. et al. Path of least recurrence: a systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection. Pharmacotherapy 2022; 42: 810-827
• 16 van Prehn J, Reigadas E, Vogelzang EH. et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults. Clin Microbiol Infec 2021; 27: S1-S21
• 17 van Nood E, Vrieze A, Nieuwdorp M. et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med 2013; 368: 407-415
• 18 Suchman K, Luo Y, Grinspan A. Fecal microbiota transplant for clostridioides difficile infection is safe and efficacious in an immunocompromised cohort. Digest Dis Sci 2022; 67: 4866-4873
• 19 Feuerstadt P, Louie TJ, Lashner B. et al. SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection. N Engl J Med 2022; 386: 220-229
• 20 Khanna S, Assi M, Lee C. et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection. Drugs 2022; 82: 1527-1538
• 21 Lee C, Louie T, Bancke L. et al. Safety of fecal microbiota, live-jslm (REBYOTATM™) in individuals with recurrent clostridioides difficile infection: data from five prospective clinical trials. Ther Adv Gastroenterol 2023; 16
• 22 Kirundi J, Moghadamrad S, Urbaniak C. Microbiome-liver crosstalk: a multihit therapeutic target for liver disease. World J Gastroenterol 2023; 29: 1651-1668
• 23 Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe 2022; 30: 289-300
• 24 Chambers ES, Byrne CS, Morrison DJ. et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut 2019; 68: 1430
• 25 Stachowska E, Maciejewska-Markiewicz D, Palma J. et al. Precision nutrition in NAFLD: effects of a high-fiber intervention on the serum metabolome of NAFD patients—a pilot study. Nutrients 2022; 14: 5355
• 26 Acharya C, Bajaj JS. Current management of hepatic encephalopathy. Am J Gastroenterol 2018; 113: 1600-1612
• 27 Sanyal AJ, Lopez P, Lawitz EJ. et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. Nat Med 2023; 29: 392-400
• 28 Koopman N, Molinaro A, Nieuwdorp M. et al. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharm Therap 2019; 50: 628-639